DGAP-Adhoc: BRAIN Biotech AG: Additional Differentiated Genome-Editing Nuclease: BRAIN-Metagenome-Cas 01 (BMC01)
|
DGAP-Ad-hoc: BRAIN Biotech AG / Key word(s): Miscellaneous/Patent
BRAIN Biotech AG: Additional Differentiated Genome-Editing Nuclease: BRAIN-Metagenome-Cas 01 (BMC01)
08-Dec-2021 / 14:53 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Additional Differentiated Genome-Editing Nuclease: BRAIN-Metagenome-Cas 01 (BMC01)
Zwingenberg, Germany, December 8th, 2021. BRAIN Biotech AG ("BRAIN") is extending its proprietary genome-editing toolbox with the addition of BRAIN-Metagenome-Cas 01 (BMC01) nuclease. In comparison to the publically recognized BRAIN-Engineered Cas (BEC), the BMC01 nuclease has a differentiated protein structure and mode of action to target DNA. BMC01 has already been filed for IP protection. This additional nuclease will extend BRAIN's proprietary genome editing competence and further enhance the overall economic potential of the platform, in case patent protection is granted.
Notifying person:
Michael Schneiders, Head of IR & Sustainability
BRAIN Biotech AG
Darmstädter Str. 34-36, 64673 Zwingenberg, Germany
www.brain-biotech.com
Investor Relations Office
Tel.: +49-(0)-6251-9331-0
Fax: +49-(0)-6251-9331-11
E-Mail: [email protected]
End of ad hoc announcement
Information and Explanation of the Issuer to this News:
About BRAIN
BRAIN Biotech AG ('BRAIN') is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.
The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.
As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals.
Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
08-Dec-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
| Language: |
English |
| Company: |
BRAIN Biotech AG |
|
Darmstädter Straße 34-36 |
|
64673 Zwingenberg |
|
Germany |
| Phone: |
+49 (0) 62 51 / 9331-0 |
| Fax: |
+49 (0) 62 51 / 9331-11 |
| E-mail: |
[email protected] |
| Internet: |
www.brain-biotech.com |
| ISIN: |
DE0005203947 |
| WKN: |
520394 |
| Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: |
1255619 |
| |
| End of Announcement |
DGAP News Service |
1255619 08-Dec-2021 CET/CEST
|
Die wichtigsten Finanzdaten auf einen Blick
|
| |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
| Umsatzerlöse1 |
24,11 |
27,05 |
38,56 |
38,23 |
38,39 |
45,51 |
55,34 |
| EBITDA1,2 |
-7,70 |
-6,55 |
-2,50 |
-3,88 |
-2,53 |
-1,31 |
-0,83 |
| EBITDA-Marge3 |
-31,94 |
-24,21 |
-6,48 |
-10,15 |
-6,59 |
-2,88 |
|
| EBIT1,4 |
-9,37 |
-9,57 |
-7,20 |
-8,23 |
-6,55 |
-5,65 |
-5,48 |
| EBIT-Marge5 |
-38,86 |
-35,38 |
-18,67 |
-21,53 |
-17,06 |
-12,42 |
-9,90 |
| Jahresüberschuss1 |
-9,40 |
-8,37 |
-11,12 |
-9,02 |
-4,68 |
-6,34 |
-8,11 |
| Netto-Marge6 |
-38,99 |
-30,94 |
-28,84 |
-23,59 |
-12,19 |
-13,93 |
-14,66 |
| Cashflow1,7 |
-5,80 |
-5,42 |
-3,38 |
-4,77 |
-3,10 |
-1,49 |
-4,22 |
| Ergebnis je Aktie8 |
-0,58 |
-0,45 |
-0,61 |
-0,52 |
-0,25 |
-0,30 |
-0,38 |
| Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen. 
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Baker Tilly
|
| INVESTOR-INFORMATIONEN |
| ©boersengefluester.de |
| BRAIN Biotech |
| WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
| 520394 |
3,000 |
Halten |
65,54 |
| KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
| 30,00 |
0,00 |
0,00 |
-6,52 |
| KBV |
KCV |
KUV |
EV/EBITDA |
| 3,01 |
- |
1,18 |
-109,11 |
| Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e
in % |
Hauptversammlung |
| 0,00 |
0,00 |
0,00 |
12.03.2024 |
| Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
| 28.02.2024 |
28.05.2024 |
29.08.2024 |
17.01.2024 |
| Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
| -16,90% |
-24,59% |
-18,03% |
-47,37% |
|
|
BRAIN Biotech AG DE0005203947